WO2013118878A1 - 環状rna及びタンパク質の製造方法 - Google Patents
環状rna及びタンパク質の製造方法 Download PDFInfo
- Publication number
- WO2013118878A1 WO2013118878A1 PCT/JP2013/053095 JP2013053095W WO2013118878A1 WO 2013118878 A1 WO2013118878 A1 WO 2013118878A1 JP 2013053095 W JP2013053095 W JP 2013053095W WO 2013118878 A1 WO2013118878 A1 WO 2013118878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- protein
- flag
- circular rna
- reaction
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Definitions
- the present invention relates to a method for producing a long protein having a repetitive sequence by carrying out rotary protein translation using a circular RNA, and a circular RNA used in the method.
- the rate-determining step of protein synthesis is an initiation step until ribosome recognizes and binds to RNA and peptide elongation starts.
- Non-Patent Document 1 protein repeats are synthesized by translation reaction of circular RNA using an E. coli cell-free translation system. Specifically, rotational protein translation using a circular RNA in which the protein ORF (open reading frame) is placed downstream of the SD (Shine-Dalgarno) sequence-start codon (AUG) -DB (downstream box) sequence as a template It is carried out.
- ORF open reading frame
- a ribosome is a complex formed by binding various translation factors to a cap structure at the 5 ′ end of mRNA and a poly A chain at the 3 ′ end. Recognizing and binding initiates the translation reaction. Therefore, when a circular RNA having no cap structure and poly A chain is used as a template, a ribosome binding site (a structure that can be recognized and bound by a ribosome) that can function as an alternative to these structures is required. It was thought.
- Non-Patent Document 2 and Patent Document 1 in a rotational protein translation reaction using a cell-free translation system derived from rabbit reticulocytes, an internal ribosome introduction site (IRES; derived from virus (EMCV)) is located upstream of the initiation codon.
- IRS internal ribosome introduction site
- EMCV derived from virus
- Non-Patent Document 1 a protein repeat (polyGFP) of GFP (green fluorescent protein) is synthesized, but the translation efficiency is lower than that of linear RNA before cyclization, and further improvement is required. Moreover, since circular RNA is prepared using a splicing reaction, there is also a problem that the synthesis of the circular RNA itself is very complicated. Furthermore, it is realized only in E. coli, and there is no application example in animal cells.
- Non-Patent Document 2 and Patent Document 1 since the circular RNA as a template has an IRES having a length of about 500 bases, the size of the circular RNA is increased, and the IRES portion Is also translated, and there is a problem that a protein translation product other than the target is generated. Further, since there is a concern about safety, there is a problem that circular RNA containing an IRES sequence is not suitable for medical applications. Furthermore, similar to the method described in Non-Patent Document 1, it is realized only with a cell-free translation system, and there is no description of application examples in animal cells.
- the present invention provides a circular RNA suitable for performing rotational protein translation with sufficiently short translation regions other than the target protein and high translation efficiency, and a method for producing a protein using the circular RNA as a template. With the goal.
- the present inventors can drastically improve the translation efficiency by making the base length of the circular RNA used as a template within a specific range in rotational protein translation.
- a circular RNA having no IRES is used as a template, it has been found that a long chain protein having a desired repetitive sequence can be synthesized. It came to be completed.
- the method for producing circular RNA and protein of the present invention has the following configurations [1] to [8].
- [1] It encodes a protein, has a full-length base number that is a multiple of 3 of 102 or more, has at least one start codon, does not have a stop codon in the same reading frame as the start codon, and further has an IRES Circular RNA that does not contain (Internal ribosome entry site).
- [2] The circular RNA according to [1], wherein the total number of bases is 561 or less.
- [4] A method for producing a protein, wherein in the eukaryotic cell expression system, the circular RNA according to any one of [1] to [3] is used as a template to express the protein encoded by the circular RNA. .
- the circular RNA according to any one of [1] to [3] is introduced into a eukaryotic cell, or the circular RNA according to any one of [1] to [3] is true.
- the method for producing a protein according to [4], wherein the protein encoded by the circular RNA is expressed by being added to a cell-free expression system derived from a nuclear cell.
- the method for producing a protein according to [4] or [5], wherein the eukaryotic cell is a mammalian cell.
- [7] It encodes a protein, and the total number of bases is a multiple of 3 between 102 and 360, and has at least one IRES and one start codon within 1 to 20 bases downstream of the IRES, Circular RNA that does not have a stop codon in the same reading frame as the start codon.
- a protein encoded by the circular RNA is expressed using the circular RNA according to the above [7] as a template.
- the long-chain protein having the desired repetitive sequence can be efficiently synthesized by the circular RNA of the present invention and the protein production method of the present invention using this as a template.
- the present invention makes it possible for the first time to carry out rotational protein translation using circular RNA as a template in human cells.
- Example 1 it is the figure which showed typically the synthetic scheme of the synthetic
- it is the nucleic acid dyeing
- it is the dyeing
- Example 1 it is the dyeing
- Example 1 it is the dyeing
- Example 2 it is the dyeing
- Example 2 it is the dyeing
- Example 2 it is the dyeing
- it is a dyeing
- it is a dyeing
- Example 2 it is a dyeing
- Example 3 it is a dyeing
- Example 4 it is the dyeing
- Example 5 it is a dyeing
- Example 6 the result of having performed the fluorescence microscope observation using a 10-times objective lens is shown.
- Example 6 the result of having performed the fluorescence microscope observation using a 60 times objective lens is shown.
- RNA for eukaryotic translation system a circular RNA serving as a template for rotational protein translation in a eukaryotic translation system (hereinafter sometimes referred to as “circular RNA for eukaryotic cells of the present invention”) encodes a protein.
- the total number of bases is a multiple of 3 greater than or equal to 102, has at least one start codon, does not have a stop codon in the same reading frame as the start codon, and does not contain IRES It is characterized by.
- IRES refers to a ribosome binding site that can function as an alternative to the cap structure.
- the circular RNA for eukaryotic cells of the present invention does not require a ribosome binding site that can function as an alternative to a cap structure such as IRES, and minimizes the sequence other than the region encoding the target protein to be synthesized. be able to. For this reason, when the circular RNA for eukaryotic cells of the present invention is used as a template, regions other than the target protein in the translated protein can be reduced. For example, it may consist of only a circular RNA having a 1 to 10 base linker for circularly linking the ends of the region encoding the target protein, or an ORF of the target protein to be synthesized. As long as the total number of bases is a multiple of 3 greater than 102 and has at least one initiation codon, it can function as a template for rotary protein translation.
- the total number of bases of the circular RNA for eukaryotic cells of the present invention is a multiple of 3 which is 102 or more. Since the total number of bases is a multiple of 3, the reading frame does not shift during translation. In addition, when the total length of the circular RNA is too short, it may not function as a template for translation reaction. However, in the present invention, since the total number of bases is 102 or more, it functions as a template for rotary protein translation. obtain.
- the upper limit of the total number of bases in the circular RNA for eukaryotic cells of the present invention is not particularly limited as long as it is a length that can function as a template for rotary protein translation, but because translation efficiency is higher, It is preferably 561 or less, more preferably 501 or less, further preferably 450 or less, and even more preferably 402 or less.
- the circular RNA for eukaryotic cells of the present invention has at least one initiation codon (for example, AUG) for expressing the target protein. From the point of homogeneity of the protein repeat to be synthesized, it is preferable that the circular RNA for eukaryotic cells of the present invention has only one start codon, but there may be two or more start codons in the same reading frame. . This is because, in the case of the same reading frame, protein repeats synthesized from the respective start codons are synthesized repeatedly, although the N-terminal portion is different. On the other hand, if there is an AUG with a different reading frame from the start codon for expressing the target protein, protein repeats other than the target protein are also translated. Preferably, the codon is modified so that it does not exist.
- AUG initiation codon
- the circular RNA for eukaryotic cells of the present invention does not have a stop codon having the same reading frame as the start codon for expressing the target protein. Therefore, it is possible to synthesize protein repeats having an infinite chain length in theory. In addition, you may have a stop codon of the reading frame different from the start codon for expressing the target protein.
- the specific base sequence of the Kozak sequence can be appropriately determined in consideration of the base sequence of the region encoding the protein to be expressed, the eukaryotic cell species of the translation system, and the like.
- RNA for prokaryotic cells of the present invention encodes a protein and has a full length. Is a multiple of 3 between 102 and 360, a ribosome binding site recognized by one prokaryotic cell-derived ribosome, and at least one initiation codon within 1 to 20 bases downstream of the ribosome binding site (for example, AUG) and no stop codon in the same reading frame as the start codon.
- AUG ribosome binding site
- the prokaryotic circular RNA of the present invention includes It is assumed that only one ribosome binds to one circular RNA and translation takes place. It is presumed that the protein synthesis of a single ribosome in which only one ribosome binds to one circular RNA eliminates the steric inhibitory effect between the ribosomes that occurs in the polyribosome and increases the efficiency of translation.
- the circular RNA for prokaryotic cells of the present invention like the circular RNA for eukaryotic cells of the present invention, has a full-length base number that is a multiple of 3, so that the reading frame does not shift during translation. Further, since it does not have a stop codon in the same reading frame as the start codon for expressing the target protein, a protein repeat having an infinite chain length can be synthesized theoretically.
- the circular RNA for prokaryotic cells of the present invention has at least one ribosome binding site.
- the ribosome binding site is not particularly limited as long as it is recognized by a prokaryotic ribosome and binds to the ribosome, and examples thereof include an SD sequence.
- the specific base sequence of the SD sequence can be determined in consideration of the species of prokaryotic cells of the translation system used.
- the circular RNA for prokaryotic cells of the present invention has one initiation codon within 1 to 20 bases downstream of the ribosome binding site. From the point of homogeneity of the protein repeat to be synthesized, the initiation codon possessed by the circular RNA for prokaryotic cells of the present invention is preferably present only within 1 to 20 bases downstream of the ribosome binding site. It may be in the part of. Even when the initiation codon is in other sites, translation from the initiation codon immediately after the ribosome binding site is preferentially performed, so that the target protein repeat can be synthesized mainly.
- circular RNA of the present invention The method for synthesizing the circular RNA for eukaryotic cells of the present invention and the circular RNA for prokaryotic cells of the present invention (hereinafter sometimes collectively referred to as “circular RNA of the present invention”) is not particularly limited.
- circular RNA can be synthesized by synthesizing single-stranded RNA by a known chemical synthesis reaction and then ligating it with ligase.
- Circular RNA can also be synthesized by synthesizing a plurality of single-stranded RNAs and then ligating them with ligase in an appropriate order.
- the ligase reaction as in the method for synthesizing circular RNA described in Non-Patent Document 2, the ligase reaction is efficiently performed by using a DNA probe that hybridizes with both ends of two single-stranded RNAs to be ligated. be able to.
- it may be prepared using a splicing reaction.
- circular RNA can be synthesized using a transcription reaction by a polymerase.
- a single-stranded RNA is synthesized by performing a transcription reaction with a polymerase in a cell-free system using a double-stranded DNA in which a base sequence complementary to the target circular RNA to be synthesized is placed downstream of the promoter sequence as a template.
- the target circular RNA can be synthesized by linking the 5 'end and the 3' end of the synthesized linear single-stranded RNA.
- the method for introducing the circular RNA of the present invention into a eukaryotic cell or a prokaryotic cell is not particularly limited, and a method known in the art such as a calcium phosphate method, a DEAE dextran method, a lipofectin method, or an electroporation method can be used. From among them, it can be appropriately selected in consideration of the cell type.
- the cell into which the circular RNA for prokaryotic cells of the present invention is introduced is not particularly limited as long as it is a prokaryotic cell, but is preferably Escherichia coli because it is widely used for expression of recombinant proteins.
- the cells into which the circular RNA for eukaryotic cells of the present invention is introduced are not particularly limited as long as they are eukaryotic cells, and may be fungi such as yeast or filamentous fungi, and may be plant cells. It may also be an animal cell such as an insect cell or a mammalian cell. For example, in the case of synthesizing a protein repeat as a material such as a pharmaceutical applied to humans, it is preferable to use human-derived cultured cells.
- the cell-free system to which the circular RNA of the present invention is added is an extracellular translation system containing all components necessary for translation such as ribosomes and tRNAs.
- eukaryotic cells or prokaryotic cell extracts can be used as the cell-free system. Any of the known eukaryotic cells and prokaryotic cells can be used, and specific examples include E. coli, thermophilic bacteria, wheat germ, rabbit reticulocytes, mouse L-cells, Ehrlich ascites tumor cells. HeLa cells, CHO cells, budding yeast, and the like, and particularly those derived from E. coli (for example, E. coli S30 cell extract) or those derived from Thermus thermophilus are desirable in terms of obtaining a high synthesis amount.
- the Escherichia coli S30 cell extract is prepared by a method known from Escherichia coli A19 (rna, met), BL21, BL21star, BL21 codon plus strain, etc. (Pratt, JM et al., Transcription and translation-a practical approach, (1984), pp. 179-209, Henes, BD and Higgins, edited by SJ, IRL Press, Oxford). Further, commercially available products from Promega and Novagen may be used. In addition to the batch method and the flow method, any conventionally known technique (see, for example, Spirin, A et al., Methods in Enzymol., 217, 123-142, 1993) can be applied.
- a long protein repeat can be easily synthesized. For this reason, when the circular RNA of the present invention has a region encoding a repetitive structure portion, a protein having a repetitive structure such as silk or collagen can be synthesized more easily.
- a region encoding a tag peptide such as a histidine tag or a Flag tag
- a protein repeat having a tag peptide in the repeated sequence structure is synthesized. it can. In this case, the synthesized protein repeat can be easily purified using the tag peptide.
- the circular RNA of the present invention has a region encoding a target protein and a region encoding a peptide that is recognized and cleaved by a protease
- by treating the protein repeat synthesized using the circular RNA as a template with a protease Multiple molecules of the target protein can be obtained from one molecule of protein repeat.
- a peptide having a relatively small molecular weight is synthesized, a circular RNA in which a plurality of regions encoding the peptide are linked may be used as a template.
- a large amount of peptides can be synthesized by using a circular RNA in which a region encoding a plurality of peptides and a region encoding a peptide recognized and cleaved by a protease between the regions are used as a template.
- the circular RNA of the present invention can be applied to the preparation of functional materials such as medical materials.
- the physiologically active peptide can be produced in the cell by introducing the circular RNA of the present invention into the cell, the circular RNA of the present invention can also be used as a new pharmaceutical product. Further, in principle, it can be used as a signal amplification mechanism rather than generating protein repeats.
- RNA oligonucleotide having a region encoding one or more FLAG peptides was synthesized, and proteins were synthesized in a cell-free system using these as templates.
- RNA oligonucleotide Preparation of oligonucleotide Specifically, first, four types of RNA oligonucleotides (F35, F49, F42, F42 ′) which are fragments of circular RNA or linear RNA, and enzyme T4 DNA ligase were used. Five types of DNA oligonucleotides (G1, G2, G3, G3 ′, G4) used as templates for the ligation reaction were respectively chemically synthesized.
- F42 ′ is 48 bases long with UAAUAA added to the 3 ′ end of F42.
- the sequence of each oligonucleotide is shown in Table 1 and SEQ ID NOs: 1 to 9 in the Sequence Listing.
- the enclosed part represents the ribosome binding sequence
- the bold base (AUG) represents the start codon
- the underlined site represents the FLAG coding sequence
- the double underline represents the stop codon.
- p indicates that the 5 ′ end is phosphorylated.
- RNA oligonucleotides All nine types were synthesized with an H-8-SE DNA synthesizer (GenWorld) using ⁇ -cyanoethyl phosphoramidite reagent (Glen Research). The RNA amidite reagent used 2'-O-TOM protector. At that time, RNA oligonucleotides (F35, F49, F42, F42 ') were all monophosphorylated at the 5' end using a chemical phosphorylation reagent (manufactured by Glen Research). All synthesized RNAs were deprotected according to a conventional method and purified by denaturing polyacrylamide gel electrophoresis (PAGE).
- PAGE denaturing polyacrylamide gel electrophoresis
- DNA oligonucleotides (G1, G2, G3, G3 ′, G4) were synthesized, deprotected according to a conventional method, and purified with a Micropure II cartridge (manufactured by Biosearch Technologies).
- a 126-base linear RNA (L126) having a region encoding three molecules of the FLAG peptide was synthesized by linking F35, F49, and F42 using G1 and G2 as templates.
- a 132-base linear RNA (L126 + stop) having a region encoding three FLAG peptides and a stop codon was synthesized by linking F35, F49, and F42 ′ using G1 and G2 as templates.
- a 132-base circular RNA (C126 + stop) having a FLAG peptide-encoding region and a stop codon was synthesized by linking F35, F49, and F42 ′ using G1, G2, and G3 ′ as templates.
- L126 L126 was synthesized by linking F35, F49, and F42 with ligase using G1 and G2 as templates.
- the ligase reaction was performed using 5 ⁇ M F35, 5 ⁇ M F49, 15 ⁇ M F42, 10 ⁇ M G1, 20 ⁇ M G2, 35 units / ⁇ L T4 DNA ligase (Takara Bio Inc.), 66 mM Tris-HCl (pH 7.6), 6
- the reaction was carried out in a reaction solution (reaction solution volume: 1.7 mL) containing 6 mM MgCl 2 , 10 mM DTT, 0.1 mM ATP, 10% (w / v) PEG6000.
- reaction solution to which all except PEG6000 and T4 DNA ligase were added was heated at 90 ° C. for 3 minutes and then gradually cooled to room temperature. Thereafter, PEG6000 and T4 DNA ligase were added to the reaction solution, and incubated at 37 ° C. for about 5 hours. An equal amount of chloroform was added to the reaction solution to extract and remove PEG6000, and then 3M aqueous sodium acetate solution (pH 5.2) and isopropyl alcohol were added and cooled to precipitate and collect RNA.
- RNA was desalted and recovered by alcohol precipitation from the concentrated extract.
- the obtained RNA (L126) was dissolved in ultrapure water, diluted appropriately, and the UV absorption spectrum was measured to calculate the yield (yield: 2.17 nmol, yield: 26%).
- FIG. 2 shows a stained image obtained as a result of staining nucleic acid in the denatured PAGE gel with SYBR Green II (manufactured by Takara Bio Inc.). Lane 1 was applied with the ssRNA marker, Lane 2 was applied with the reaction solution before the enzyme reaction, and Lane 3 was applied with the reaction solution after the enzyme reaction. As shown in FIG. 2, L126 was synthesized from F35, F49, and F42 after the enzymatic reaction.
- C126 C126 was synthesized by cyclizing L126 by ligase reaction.
- the ligase reaction was performed using 1 ⁇ M L126, 1 ⁇ M G3, 17.5 units / ⁇ L T4 DNA ligase (Takara Bio), 6 mM Tris-HCl (pH 7.6), 6.6 mM MgCl 2 , 10 mM DTT, The reaction was carried out in a reaction solution containing 0.1 mM ATP, 10% (w / v) PEG6000 (reaction solution amount: 2 mL). Specifically, the reaction solution to which all except PEG6000 and T4 DNA ligase were added was heated at 90 ° C. for 3 minutes and then gradually cooled to room temperature.
- the ligation product (C126) was isolated from the remaining RNA using the same denaturing PAGE.
- the band containing the target product was visualized by UV shadowing, cut out and finely pulverized, and then RNA was extracted twice with 0.5 mL of the eluate [10 mM EDTA (pH 8.0)].
- the obtained extract was concentrated using a centrifugal evaporator, and further concentrated using Microcon YM-3 (Millipore). RNA was desalted and recovered by alcohol precipitation from the concentrated extract.
- FIG. 3 shows a stained image obtained as a result of staining the modified PAGE gel with SYBR Green II (manufactured by Takara Bio Inc.). Lane 1 was applied with the ssRNA marker, Lane 2 was applied with the reaction solution before the enzyme reaction, and Lane 3 was applied with the reaction solution after the enzyme reaction. As shown in FIG. 3, C126 was synthesized from L126 after the enzyme reaction.
- FIG. 4 shows a stained image obtained as a result of 8% denaturing PAGE analysis of a reaction product of ligase reaction for synthesizing L84 (84 base linear RNA having a region encoding two molecules of FLAG peptide). Show. Lane 1 applied the reaction solution before the enzyme reaction, Lane 2 applied the reaction solution after the enzyme reaction, and Lane M applied the ssRNA marker. As shown in FIG. 4, L84 was synthesized from F35 and F49 after the enzyme reaction. FIG.
- Lane 5 shows a stained image obtained as a result of 8% denaturing PAGE analysis of the reaction product of the circular RNA synthesis reaction.
- Lane 1 is the reaction solution before the ligase reaction using L84 as a template
- Lane 2 is the reaction solution after the ligase reaction using L84 as a template
- Lane M is the ssRNA marker
- Lane 3 is the L126 template.
- Lane 4 shows the reaction solution before the ligase reaction
- Lane 4 shows the reaction solution after the ligase reaction using L126 as a template.
- L84 to C84 and C168 and L126 to C126 and C252 were synthesized, respectively.
- Sample 1 ⁇ L from the reaction solution 5 ⁇ L 2 ⁇ sample buffer [0.125 M Tris-HCl (pH 8.0), 2% SDS, 30% glycerol, 0.02% bromophenol blue, 5% 2-mercaptoethanol] And 4 ⁇ L of ultrapure water. This was heated at 95 ° C. for 5 minutes and then electrophoresed using a 10-20% gradient polyacrylamide gel (manufactured by ATTO) (electrophoresis buffer: 25 mM Tris-HCl, 0.1% SDS, 192 mM glycine).
- sample buffer 0.125 M Tris-HCl (pH 8.0), 2% SDS, 30% glycerol, 0.02% bromophenol blue, 5% 2-mercaptoethanol
- FIG. 6 shows the result of visualizing a protein band containing FLAG.
- Lane 1 is a reaction solution to which L126 is added
- Lane 2 is a reaction solution to which L126 + stop is added
- Lane 3 is a reaction solution to which C126 + stop is added
- Lane 4 is a reaction solution to which C126 is added
- Lane 5 is a reaction solution to which no RNA is added.
- Lanes 1 and 3 are reaction solutions without addition of RNA
- lane 2 is a reaction solution with addition of C84
- lane 4 is a reaction solution with addition of C126
- lane 5 is a reaction solution with addition of C168
- lane 6 is a reaction with addition of C252.
- Each solution was applied.
- FIG. 7 when C84 was used as a template, a long-chain peptide that was a reaction product of continuous translation reaction was not generated.
- C126, C168, and C252 were used as templates, the generation of long-chain peptides (protein repeats) that were reaction products of continuous translation reaction was observed.
- C126 and C168 were used as templates, translation efficiency was higher and a larger amount of protein repeat was synthesized than when C252 was used as a template.
- Circular RNA for eukaryotic cells having a region encoding a plurality of FLAG peptides was synthesized, and proteins were synthesized in a cell-free system derived from rabbits using these as templates.
- Eukaryotic circular RNA was synthesized using a transcription reaction by polymerase. First, DNA oligonucleotides were synthesized with a DNA synthesizer (Fragment 1 to Fragment 3 in Table 3; these sequences are shown in SEQ ID NOs: 15 to 17), and ligated with T4 DNA ligase, and then 155 by annealing or PCR method.
- Double-stranded DNA oligonucleotides (template DNA) of 284, 290, 413 base pairs were synthesized (Tables 4 and 5).
- template DNA template DNA
- in vitro transcription with T7 RNA polymerase was performed using the double-stranded DNA oligonucleotide as a template to synthesize linear single-stranded RNAs of 129, 258, 264, and 387 bases (Tables 6 and 7), and T4 Circular RNA was synthesized by ligating the 5 ′ end and 3 ′ end using RNA ligase. Details are shown below.
- Table 3 shows the sequences of various oligonucleotides used as templates for polymerase reaction.
- p indicates that the 5 ′ end is phosphorylated.
- DNA oligonucleotides were synthesized with an H-8-SE DNA synthesizer (GenWorld) using ⁇ -cyanoethyl phosphoramidite reagent (Glen Research). Fragment 1 and Fragment 2 were monophosphorylated at the 5 ′ end using a chemical phosphorylation reagent (manufactured by Glen Research).
- Each oligonucleotide was deprotected according to a standard method and purified with a Micropure II cartridge (manufactured by Biosearch Technologies). Fragment1, Fragment2, Fragment3, and Fragment1 DNA sense were further purified by denaturing PAGE.
- An antisense strand is synthesized by purification by denaturing PAGE, and the antisense strand and Forward primer 1 (SEQ ID NO: 21) are double-stranded by PCR using PrimeSTAR (registered trademark) HS DNA Polymerase (manufactured by Takara Bio Inc.). DNA was synthesized and purified by QIAquick PCR Purification Kit (manufactured by QIAGEN). 12 ⁇ FLAG DNA (SEQ ID NO: 38) was obtained by using Fragment 1 (SEQ ID NO: 15), Fragment 2 (SEQ ID NO: 16), and Fragment 3 (SEQ ID NO: 17) using Adapter 2 (SEQ ID NO: 19) and Adapter 3 (SEQ ID NO: 20) as templates.
- An antisense strand was synthesized by ligation using T4 DNA ligase, and the resulting ligation product was purified by denaturing PAGE.
- the antisense strand and Forward primer 1 (SEQ ID NO: 21) were then converted to PrimeSTAR (registered trademark) HS DNA Polymerase.
- a double-stranded DNA was synthesized by PCR using Takara Bio, and purified by QIAquick PCR Purification Kit (QIAGEN).
- 8 ⁇ FLAG (2) DNA (SEQ ID NO: 39) and 8 ⁇ FLAG (stop) DNA (SEQ ID NO: 40) were obtained using 12 ⁇ FLAG DNA (SEQ ID NO: 38) as a template and Forward primer 1 (SEQ ID NO: 21) and Reverse, respectively.
- Primer 3 (SEQ ID NO: 24), or Forward primer 1 (SEQ ID NO: 21) and Reverse primer 4 (SEQ ID NO: 28) are used as primers, and PrimeSTAR (registered trademark) HS DNA Polymerase (manufactured by Takara Bio Inc.) is used as a double strand by PCR.
- DNA was synthesized and purified by QIAquick PCR Purification Kit (manufactured by QIAGEN).
- 8 ⁇ FLAG (3) DNA (SEQ ID NO: 41) was obtained using PrimeSTAR with 8 ⁇ FLAG (2) DNA (SEQ ID NO: 39) as a template, Forward primer 2 (SEQ ID NO: 35) and Reverse primer 5 (SEQ ID NO: 31) as primers.
- Double-stranded DNA was synthesized by PCR using (registered trademark) HS DNA Polymerase (manufactured by Takara Bio Inc.) and purified by QIAquick PCR Purification Kit (manufactured by QIAGEN).
- 8 ⁇ FLAG (3 stop) DNA (SEQ ID NO: 42) was prepared using 8 ⁇ FLAG (stop) DNA (SEQ ID NO: 40) as a template, Forward primer 2 (SEQ ID NO: 35) and Reverse primer 6 (SEQ ID NO: 32) as primers.
- Double-stranded DNA was synthesized by PCR using PrimeSTAR (registered trademark) HS DNA Polymerase (manufactured by Takara Bio Inc.), and purified by QIAquick PCR Purification Kit (manufactured by QIAGEN).
- PrimeSTAR registered trademark
- HS DNA Polymerase manufactured by Takara Bio Inc.
- QIAquick PCR Purification Kit manufactured by QIAGEN.
- 4 ⁇ FLAG RNA (SEQ ID NO: 43), 8 ⁇ FLAG RNA (SEQ ID NO: 44), and 12 ⁇ FLAG RNA (SEQ ID NO: 45) are respectively 4 ⁇ FLAG DNA (SEQ ID NO: 36), 8 ⁇ FLAG DNA (SEQ ID NO: 45). 37) and 12 ⁇ FLAG DNA (SEQ ID NO: 38) were synthesized as templates. Specifically, T7 RNA Polymerase (manufactured by Takara Bio Inc.) was used.
- reaction liquid volume 1 mL
- reaction liquid volume 1 mL
- RNA was recovered, and linear RNA as a transcription product was isolated using denatured PAGE (5% polyacrylamide, 7.5 M urea, 25% formamide, 1 ⁇ TBE, 1 mm thickness).
- the band containing the target product was visualized by the UV shadowing method, cut out, finely pulverized, and extracted with an eluent [10 mM EDTA (pH 8.0)].
- the extract was desalted with a Sep-Pak C18 cartridge (manufactured by Waters), eluted with 50% acetonitrile, concentrated with a centrifugal evaporator, and lyophilized.
- RNA was desalted and recovered from the lyophilized product by alcohol precipitation.
- RNA was dissolved in ultrapure water, diluted appropriately, and the UV absorption spectrum was measured to calculate the yield (4 ⁇ FLAG RNA yield: 3.56 nmol, 8 ⁇ FLAG RNA yield: 10.06 nmol, 12 X Yield of FLAG RNA: 5.75 nmol).
- 8 x FLAG (2) RNA (SEQ ID NO: 46), 8 x FLAG (stop) RNA (SEQ ID NO: 47), 8 x FLAG (3) RNA (SEQ ID NO: 48), and 8 x FLAG (3 stop) RNA (sequence) No. 49) are MEGAscript (registered trademark) T7 Kit (8 ⁇ FLAG (2) DNA, 8 ⁇ FLAG (stop) DNA, 8 ⁇ FLAG (3) DNA, and 8 ⁇ FLAG (3 stop) DNA, respectively, as templates. Ambion).
- reaction liquid volume 400 ⁇ L (however, the reaction liquid volume of 8 ⁇ FLAG (stop) RNA was 600 ⁇ L).
- reaction liquid volume of 8 ⁇ FLAG (stop) RNA was 600 ⁇ L.
- Each reaction solution was incubated at 37 ° C. for about 16 hours (however, 8 ⁇ FLAG (3) RNA and 8 ⁇ FLAG (3 stop) RNA were 6 hours) to carry out a transcription reaction.
- TURBO DNase attached to the Kit was added to the reaction solution, and the template DNA was decomposed according to the product manual.
- TE-saturated phenol-chloroform mixture (5: 1) was added to each reaction solution to extract the nucleic acid, 3M aqueous sodium acetate solution (pH 5.2) and isopropyl alcohol were added, and alcohol precipitation was performed.
- RNA was recovered, and linear RNA as a transcription product was isolated using denatured PAGE (5% polyacrylamide, 7.5M urea, 25% formamide, 1 ⁇ TBE, 1 mm thickness). The band containing the target product was visualized by the UV shadowing method, cut out, finely pulverized, and extracted with an eluent [10 mM EDTA (pH 8.0)].
- Extraction total amount (however, 8 ⁇ FLAG (3) RNA and 8 ⁇ FLAG (3 stop) RNA is 1/4 of the total amount of extraction solution) Amicon Ultra-0.5 mL (fractionated molecular weight: 3K) (Millipore) ) Or Amicon Ultra-4 (fractionated molecular weight: 3K) (Millipore) and then recovered.
- RNA and 8 ⁇ FLAG (3 stop) RNA (3/4 of the total amount of the extract) was desalted with a Sep-Pak C18 cartridge (manufactured by Waters), then 50 After elution with% acetonitrile, concentration with a centrifugal evaporator and lyophilization, RNA was desalted and recovered from the lyophilized product by alcohol precipitation. The obtained RNA was dissolved in ultrapure water, and after appropriate dilution, the UV absorption spectrum was measured to calculate the yield (8 ⁇ FLAG (2) RNA yield: 0.975 nmol, 8 ⁇ FLAG (stop) RNA yield. : 2.01 nmol, 8 ⁇ FLAG (3) RNA yield: 1.56 nmol, 8 ⁇ FLAG (3 stop) RNA yield: 2.34 nmol).
- Adapter 4 (SEQ ID NO: 29) to 8 ⁇ FLAG (2) RNA (SEQ ID NO: 46) to 8 ⁇ FLAG (2) RNA cyclized form
- Adapter 5 (SEQ ID NO: 29) 30) is used to convert an 8 ⁇ FLAG (stop) RNA (SEQ ID NO: 47) to an 8 ⁇ FLAG (stop) RNA cyclized product from A 8 ⁇ FLAG (3) RNA (SEQ ID NO: 48) to 8 ⁇ FLAG (3) RNA cyclized product using adapter 6 (SEQ ID NO: 33), 8 ⁇ FLAG (3 stop) using Adapter 7 (SEQ ID NO: 34) 8 ⁇ FLAG (3 stop) RNA cyclized products were synthesized from RNA (SEQ ID NO: 49) by ligase reaction.
- the ligase reaction was performed using 1 ⁇ M transcribed RNA, 5 ⁇ M DNA oligonucleotide (Adaptors 1 to 7), 0.0125 units / ⁇ L T4 RNA ligase 2 (manufactured by New England Biolabs), 50 mM Tris-HCl (pH 7.5).
- Reaction solution containing 2 mM MgCl 2 , 1 mM DTT, 0.4 mM ATP (reaction solution volume: 800 ⁇ L (provided that the reaction solution of 4 ⁇ FLAG RNA is 3000 ⁇ L, the reaction solution of 8 ⁇ FLAG RNA and 12 ⁇ FLAG RNA is 5000 ⁇ L, The reaction solution of 8 ⁇ FLAG (3) RNA was 600 ⁇ L, and the reaction solution of 8 ⁇ FLAG (3 stop) RNA was 1000 ⁇ L).
- reaction solution to which all except T4 RNA ligase 2 was added was heated at 90 ° C. for 3 minutes and then gradually cooled to room temperature. Thereafter, T4 DNA ligase 2 was added to the reaction solution and incubated at 37 ° C. for 3 hours (however, the reaction solution of 8 ⁇ FLAG (2) RNA and 8 ⁇ FLAG (2 stop) RNA was about 16 hours).
- denatured PAGE 5% polyacrylamide, 7.5M urea, 25% formamide, 1 ⁇ TBE, 1 mm thickness
- the band containing the target product was visualized and cut out finely by UV shadowing, and then extracted with an eluent [10 mM EDTA (pH 8.0)].
- the extract was desalted with Amicon Ultra-0.5 mL (fraction molecular weight: 3K) (Millipore) or Amicon Ultra-4 (fraction molecular weight: 3K) (Millipore) and concentrated, and then the RNA was alcohol precipitated. By desalting and recovery.
- the reaction solution of 4 ⁇ FLAG RNA, 8 ⁇ FLAG RNA, and 12 ⁇ FLAG RNA was desalted and concentrated using Amicon Ultra-0.5 mL or the like, and then further Microcon Ultracell YM-10 (fractionated molecular weight: After desalting and concentration at 10K), RNA was recovered by alcohol precipitation.
- RNA was dissolved in ultrapure water, and after appropriate dilution, the UV absorption spectrum was measured, and the yield was calculated (4 ⁇ FLAG RNA cyclized product yield: 375 pmol (yield: 12.5%), 8 ⁇ Yield of FLAG RNA cyclized product: 396 pmol (yield: 7.93%), 12 ⁇ FLAG RNA cyclized product yield: 253 pmol (yield: 5.05%), 8 ⁇ FLAG (2) RNA cyclized product Yield: 69.99 pmol (yield: 8.75%), 8 ⁇ FLAG (stop) RNA cyclized product yield: 56.71 pmol (yield: 7.09%), 8 ⁇ FLAG (3) RNA circle Yield: 35.56 pmol (yield: 5.93%), 8 ⁇ FLAG (3 stop) RNA cyclized product yield: 84.82 pmol (yield: 8.48%)).
- FIGS. 8 to 10 show stained images obtained as a result of electrophoresis of each cyclized product after purification by denaturing PAGE and staining with SYBR Green II (manufactured by Takara Bio Inc.).
- lane 1 is 4 ⁇ FLAG RNA
- lane 2 is 4 ⁇ FLAG RNA cyclized
- lane 3 is 8 ⁇ FLAG RNA
- lane 4 is 8 ⁇ FLAG RNA cyclized
- lane 5 is 12 ⁇ .
- FLAG RNA was applied to Lane 6 and 12 ⁇ FLAG RNA cyclized product was applied thereto.
- FIG. 8 shows stained images obtained as a result of electrophoresis of each cyclized product after purification by denaturing PAGE and staining with SYBR Green II (manufactured by Takara Bio Inc.).
- lane 1 is 4 ⁇ FLAG RNA
- lane 3 is 8 ⁇ FLAG RNA
- lane 4 is 8 ⁇ FLAG RNA cyclized
- lane 1 is 8 ⁇ FLAG (2) DNA
- lane 2 is 8 ⁇ FLAG (2) RNA
- lane 3 is 8 ⁇ FLAG (2) RNA cyclized product
- lane 4 is 8 ⁇ FLAG (stop). ) DNA
- lane 5 was applied with 8 ⁇ FLAG (stop) RNA
- lane 6 was applied with 8 ⁇ FLAG (stop) RNA cyclized product.
- FIG. 9 lane 1 is 8 ⁇ FLAG (2) DNA
- lane 2 is 8 ⁇ FLAG (2) RNA
- lane 3 is 8 ⁇ FLAG (2) RNA cyclized product
- lane 4 is 8 ⁇ FLAG (stop).
- lane 1 is 8 ⁇ FLAG (3) DNA
- lane 2 is 8 ⁇ FLAG (3) RNA
- lane 3 is 8 ⁇ FLAG (3) RNA cyclized product
- lane 4 is 8 ⁇ FLAG (3 stop) DNA
- lane 5 was applied with 8 ⁇ FLAG (3 stop) RNA
- lane 6 was applied with 8 ⁇ FLAG (3 stop) RNA cyclized product.
- RNA after quenching 70% Rabbit Reticulocyte Lysate (Promega), 10 ⁇ M Amino Acid Mix Minus Methionine, 10 ⁇ M Amino Acid Mix Minus Lit )), 0.8 units / ⁇ L RNase Inhibitor (Toyobo Co., Ltd.) as a reaction solution (reaction solution volume: 25 ⁇ L), and each reaction solution is incubated at 30 ° C. for 1.5 to 19 hours to perform a translation reaction. It was.
- FIGS. 11 to 14 show the results of visualizing a protein band containing FLAG. Reaction solutions listed in Tables 8 to 11 were applied to the lanes of FIGS.
- Example 3 Using the RNA cyclized product synthesized in Example 2 and the linear transcribed RNA before cyclization as a template, a protein was synthesized in a human cell-free system.
- the translation reaction was performed according to the product manual using an AvidExpress (registered trademark) Cell-Free Translation System (derived from human HeLaS3 cells, manufactured by Avidity) so that the template RNA had a final concentration of 1.2 ⁇ M.
- 2.5 ⁇ L is sampled from each reaction solution, and electrophoresed using a 10-20% gradient polyacrylamide gel in the same manner as in Example 2. After the protein developed in the gel is transferred to the PVDF membrane, Anti-FLAG antibody and anti-mouse IgG antibody HRP complex were reacted and reacted with an HRP substrate to visualize a FLAG sequence-specific protein band.
- FIG. 15 shows the result of visualizing a protein band containing FLAG.
- lane 1 contains a reaction solution without RNA
- lane 2 shows a reaction solution added with 4 ⁇ FLAG RNA
- lane 3 shows a reaction solution added with 4 ⁇ FLAG RNA cyclized product
- lane 4 shows 8 reaction solutions.
- lane 5 is the reaction solution added with 8 ⁇ FLAG RNA cyclized product
- lane 6 is the reaction solution added with 12 ⁇ FLAG RNA
- lane 7 is the 12 ⁇ FLAG RNA cyclization.
- Each reaction solution to which the body was added was applied. As shown in FIG.
- Example 4 Using the RNA cyclized product synthesized in Example 2 and the linear transcribed RNA before cyclization as a template, a protein was synthesized using a translation system in human cells. First, 145 ⁇ L of Opti-MEM I Reduced-Serum Medium (manufactured by Invitrogen) and 5 ⁇ L of 2.4 ⁇ M template RNA solution were mixed per well with a 12-well plate for cell culture (manufactured by Nippon Becton Dickinson), and Lipofectamine RNAiMAX. 2 ⁇ L (Invitrogen) was added and mixed, and allowed to stand for 15 minutes.
- Opti-MEM I Reduced-Serum Medium manufactured by Invitrogen
- 5 ⁇ L of 2.4 ⁇ M template RNA solution were mixed per well with a 12-well plate for cell culture (manufactured by Nippon Becton Dickinson), and Lipofectamine RNAiMAX. 2 ⁇ L (Invitrogen) was added
- HeLa cells human cervical cancer
- Dulbecco's Modified Eagle Medium manufactured by Wako Pure Chemical Industries
- 10% fetal bovine serum manufactured by Invitrogen
- 850 ⁇ L of a cultured cell line derived from RIKEN BioResource Center was added and cultured in a 37 ° C., 5% CO 2 environment for 24 hours (final RNA concentration: 12 nM).
- cell lysis buffer manufactured by CST Japan
- Example 2 7.5 ⁇ L of the obtained supernatant was sampled and electrophoresed using a 10-20% gradient polyacrylamide gel in the same manner as in Example 2, and the protein developed in the gel was transferred to a PVDF membrane. Thereafter, an anti-FLAG antibody or an anti-actin antibody (manufactured by Santa Cruz Biotechnology), an anti-mouse IgG antibody HRP complex is reacted, and reacted with an HRP substrate to produce a FLAG sequence-specific protein band or an actin protein band. Visualized.
- an anti-FLAG antibody or an anti-actin antibody manufactured by Santa Cruz Biotechnology
- an anti-mouse IgG antibody HRP complex is reacted, and reacted with an HRP substrate to produce a FLAG sequence-specific protein band or an actin protein band.
- FIG. 16 shows the results of visualizing FLAG-containing protein and actin protein bands.
- lane 1 is a reaction solution without RNA
- lane 2 is a reaction solution to which 8 ⁇ FLAG (2) RNA is added
- lane 3 is a reaction solution to which 8 ⁇ FLAG (2) RNA cyclized product is added.
- Lane 4 the reaction solution to which 8 ⁇ FLAG (stop) RNA was added was applied
- Lane 5 the reaction solution to which 8 ⁇ FLAG (stop) RNA cyclized product was added was applied.
- a high molecular weight translation product (protein repeat) was detected when 8 ⁇ FLAG (2) RNA cyclized product was used as a template (lane 3).
- Example 5 Using the RNA cyclized product synthesized in Example 2 and the linear transcribed RNA before cyclization as a template, a protein was synthesized using a translation system in human cells. First, 45- ⁇ L of Opti-MEM I Reduced-Serum Medium (manufactured by Invitrogen) and 4 ⁇ L of 2 ⁇ M template RNA solution were mixed per well with a 24-well plate for cell culture (manufactured by Nippon Becton Dickinson), and Lipofectamine RNAiMAX (Invitrogen). 1 ⁇ L) was added and mixed, and allowed to stand for 15 minutes.
- HeLa cells diluted to 143,000 cells per mL using Dulbecco's Modified Eagle Medium (manufactured by Wako Pure Chemical Industries, Ltd.) containing 10% fetal bovine serum was added to the mixture at 37 ° C., 5% CO 2.
- the cells were cultured in the environment for 24 hours (RNA final concentration: 20 nM).
- cell lysis buffer manufactured by CST Japan
- centrifugation was performed.
- the amount of protein in the obtained supernatant was measured using Coomassie Plus (manufactured by Thermo Fisher Scientific), and the protein concentration was adjusted to 1.5 mg / mL using a cell lysis buffer.
- Example 2 After adjusting the protein concentration, 7.5 ⁇ L was sampled and electrophoresed using a 10-20% gradient polyacrylamide gel in the same manner as in Example 2, and the protein developed in the gel was transferred to a PVDF membrane. Thereafter, an anti-FLAG antibody or an anti-actin antibody (manufactured by Santa Cruz Biotechnology), an anti-mouse IgG antibody HRP complex is reacted, and reacted with an HRP substrate to produce a FLAG sequence-specific protein band or an actin protein band. Visualization (ChemiDoc XRS Plus, manufactured by Bio-Rad Laboratories) was performed.
- FIG. 17 shows the results of visualizing FLAG-containing protein and actin protein bands.
- lane 1 is a reaction solution without RNA
- lane 2 is a reaction solution to which 8 ⁇ FLAG (3) RNA is added
- lane 3 is a reaction solution to which 8 ⁇ FLAG (3) RNA cyclized product is added.
- lane 4 a reaction solution to which 8 ⁇ FLAG (3 stop) RNA was added was applied
- lane 5 a reaction solution to which 8 ⁇ FLAG (3 stop) RNA cyclized product was added was applied.
- lane 3 shows that a high molecular weight translation product (protein repeat) was detected.
- the actin protein bands were almost the same in all lanes, it was shown that the amount of protein in the cell lysate added to each reaction solution was the same.
- Example 6 The circular RNA of 8 ⁇ FLAG RNA synthesized in (2) of Example 2 was transfected into HeLa cells, and the RNA translation product introduced into the cells was stained by cell staining using a fluorescently labeled anti-FALG antibody. Detection was performed. First, Dulbecco's Modified Eagle Medium (manufactured by Wako Pure Chemical Industries, Ltd.) containing 10% fetal bovine serum was used in a 24-well plate for cell culture (manufactured by Nippon Becton Dickinson) with cover glass in each well. Then, 500 ⁇ l of HeLa cells diluted to 100,000 cells per mL were added and cultured overnight at 37 ° C. in a 5% CO 2 environment.
- Dulbecco's Modified Eagle Medium manufactured by Wako Pure Chemical Industries, Ltd.
- 10% fetal bovine serum was used in a 24-well plate for cell culture (manufactured by Nippon Becton Dickinson) with cover glass in each well.
- Opti-MEM I Reduced-Serum Medium manufactured by Invitrogen
- Opti-MEM I Reduced-Serum Medium 32.5 ⁇ L and 2 ⁇ g / mL template RNA solution 2.5 ⁇ L were mixed, and Opti-MEM I Reduced-Serum Medium (manufactured by Invitrogen) 12 ⁇ L and Oligofectamine A solution mixed with 3 ⁇ L (manufactured by Invitrogen) was added, allowed to stand for 15 minutes, added to each well, and cultured at 37 ° C. in a 5% CO 2 environment for 6 hours.
- Dulbecco's Modified Eagle Medium (manufactured by Wako Pure Chemical Industries, Ltd.) containing 10% fetal bovine serum was added at 500 ⁇ L per well, and further at 37 ° C. in a 5% CO 2 environment. Cultured for 24 hours. Thereafter, the medium was removed, and after washing, the cells were fixed with 4% PFA / PBS. Cells were treated with 0.3% Triton X-100 / PBS, then blocked with 1% BSA / PBS, and then mouse anti-FLAG antibody prepared with 1% BSA / PBS (Sigma Aldrich Japan GK) Was added and incubated for 1 hour.
- Alexa Floor 488-labeled anti-mouse IgG antibody prepared with 1% BSA / PBS was added and incubated for 1 hour. Microscopic observation was performed after washing. The results are shown in FIGS.
- protein repeats can be easily synthesized not only in cell-free systems but also in cells by the circular RNA of the present invention and the protein production method using the circular RNA, not only in academic fields such as research. In addition, it is preferably used in the field of production of pharmaceuticals, foods and drinks, cosmetics, chemical products and the like using peptides and proteins.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
[1] タンパク質をコードし、全長の塩基数が102以上の3の倍数であり、少なくとも1の開始コドンを有し、前記開始コドンと同じ読み枠の終止コドンを有しておらず、さらにIRES(Internal ribosome entry site)を含んでいない、環状RNA。
[2] 全長の塩基数が、561以下である、前記[1]に記載の環状RNA。
[3] 前記開始コドンの上流にKozak配列を有する前記[1]又は[2]に記載の環状RNA。
[4] 真核細胞の発現系において、前記[1]~[3]のいずれか一つに記載の環状RNAを鋳型として、当該環状RNAがコードしているタンパク質を発現させる、タンパク質の製造方法。
[5] 前記[1]~[3]のいずれか一つに記載の環状RNAを真核細胞に導入する、又は前記[1]~[3]のいずれか一つに記載の環状RNAを真核細胞由来の無細胞発現系に添加することにより、当該環状RNAがコードしているタンパク質を発現させる前記[4]に記載のタンパク質の製造方法。
[6] 前記真核細胞が哺乳細胞である前記[4]又は[5]に記載のタンパク質の製造方法。
[7] タンパク質をコードし、全長の塩基数が102以上360以下の3の倍数であり、少なくとも一つのIRESと、前記IRESの下流1~20塩基以内に一つの開始コドンを有しており、前記開始コドンと同じ読み枠の終止コドンを有していない、環状RNA。
[8] 原核細胞の発現系において、前記[7]に記載の環状RNAを鋳型として、当該環状RNAがコードしているタンパク質を発現させることを特徴とする、タンパク質の製造方法。
本発明の環状RNAのうち、真核細胞の翻訳系において回転式タンパク質翻訳の鋳型となる環状RNA(以下、「本発明の真核細胞用環状RNA」ということがある)は、タンパク質をコードし、全長の塩基数が102以上の3の倍数であり、少なくとも1の開始コドンを有しており、前記開始コドンと同じ読み枠の終止コドンを有しておらず、さらにIRESを含んでいないことを特徴とする。IRESとは、キャップ構造の代替として機能し得るリボソーム結合部位をいう。IRESを有していない環状RNAを鋳型とした場合に動物細胞翻訳系において回転式タンパク質翻訳が可能であることや、無細胞系ではなく、動物細胞内で回転式タンパク質翻訳が起こることは、本発明者らによって初めて明らかにされた。
本発明の環状RNAのうち、原核細胞の翻訳系において回転式タンパク質翻訳の鋳型となる環状RNA(以下、「本発明の原核細胞用環状RNA」ということがある)は、タンパク質をコードし、全長の塩基数が102以上360以下の3の倍数であり、1の原核細胞由来のリボソームが認識するリボソーム結合部位と、前記リボソーム結合部位の下流1~20塩基以内に少なくとも1の開始コドン(例えば、AUG)を有しており、前記開始コドンと同じ読み枠の終止コドンを有していないことを特徴とする。全長の塩基数が102以上360以下であることにより、原核細胞の翻訳系において、翻訳効率を顕著に高めることができる。
本発明の真核細胞用環状RNA及び本発明の原核細胞用環状RNA(以下、合わせて「本発明の環状RNA」ということがある)の合成方法は特に限定されるものではない。例えば、公知の化学合成反応により一本鎖RNAを合成した後、これをリガーゼにより連結することで環状RNAを合成することができる。複数本の一本鎖RNAを合成した後、これらをそれぞれ適切な順番にリガーゼにより連結することによっても、環状RNAを合成することができる。リガーゼ反応の際に、非特許文献2に記載の環状RNAの合成方法と同様に、連結させる2本の一本鎖RNAの両端とハイブリダイズするDNAプローブを用いることにより、効率よくリガーゼ反応を行うことができる。その他、非特許文献1に記載の環状RNAの合成方法と同様に、スプライシング反応を利用して調製してもよい。
本発明の真核細胞用環状RNAを真核細胞に導入する、又は真核細胞由来の無細胞発現系に添加することにより、当該真核細胞用環状RNAがコードしているタンパク質を繰り返し配列構造として有するタンパク質リピートが翻訳され、合成される。同様に、本発明の原核細胞用環状RNAを原核細胞に導入する、又は原核細胞由来の無細胞発現系に添加することにより、当該原核細胞用環状RNAがコードしているタンパク質を繰り返し配列構造として有するタンパク質リピートが翻訳され、合成される。本発明の環状RNAを鋳型とする回転式タンパク質翻訳においては、リボソームが一度環状RNAに結合し、タンパク質合成を開始すると、原理的には永久にタンパク質合成が進行する。つまり、翻訳開始の律速段階は最初のリボソーム結合時のみであり、それ以降のタンパク質合成は効率よく行われるという利点がある。
当該大腸菌S30細胞抽出液は、大腸菌A19(rna、met)、BL21、BL21star、BL21コドンプラス株等から公知の方法(Pratt, J.M. et al., Transcription and translation - a practical approach, (1984), pp.179-209, Henes, B.D.とHiggins, S.J.編、IRL Press, Oxford参照)に従って調製できる。また、プロメガ社やノバジェン社から市販されるものを使用してもよい。また、バッチ法、フロー法の他、従来公知の技術(例えば、Spirin, A et al., Methods in Enzymol., 217, 123-142, 1993参照)がいずれも適用可能である。
1又は複数のFLAGペプチドをコードする領域を有する原核細胞用環状RNAを合成し、これらを鋳型として無細胞系においてタンパク質を合成した。
<環状RNAの合成>
(1)オリゴヌクレオチドの調製
具体的には、まず、環状RNA又は直鎖状RNAのフラグメントである4種類のRNAオリゴヌクレオチド(F35、F49、F42、F42’)、及び酵素T4 DNAリガーゼを用いた連結反応に鋳型として用いる5種類のDNAオリゴヌクレオチド(G1、G2、G3、G3’、G4)をそれぞれ化学合成した。なお、F42’は、F42の3’末端にUAAUAAを付加した48塩基長である。各オリゴヌクレオチドの配列を表1、及び配列表の配列番号1~9に示す。表1中、囲み部分はリボソーム結合配列を表し、太字の塩基(AUG)は開始コドンを表し、下線部位はFLAGコード配列を表し、二重下線部は終止コドンを表す。pは5’末端がリン酸化されていることを示す。
2分子のFLAGペプチドをコードする領域を有する84塩基の環状RNA(C84)及び4分子のFLAGペプチドをコードする領域を有する168塩基の環状RNA(C168)は、F35及びF49を、G1及びG4を鋳型として連結することにより合成した。3分子のFLAGペプチドをコードする領域を有する126塩基の環状RNA(C126)及び6分子のFLAGペプチドをコードする領域を有する252塩基の環状RNA(C252)は、F35、F49、及びF42を、G1、G2、及びG3を鋳型として連結することにより合成した。各合成スキームを模式的に図1に示す。
また、3分子のFLAGペプチドをコードする領域を有する126塩基の直鎖状RNA(L126)は、F35、F49、及びF42を、G1及びG2を鋳型として連結することにより合成した。3分子のFLAGペプチドをコードする領域及び終止コドンを有する132塩基の直鎖状RNA(L126+stop)は、F35、F49、及びF42’を、G1及びG2を鋳型として連結することにより合成し、3分子のFLAGペプチドをコードする領域及び終止コドンを有する132塩基の環状RNA(C126+stop)は、F35、F49、及びF42’を、G1、G2、及びG3’を鋳型として連結することにより合成した。
C84、C126、C168、C252、C126+stopの配列を表2、及び配列表の配列番号10~14に示す。表2中、囲み部分はリボソーム結合配列を表し、太字の塩基(AUG)は開始コドンを表し、下線部位はFLAGコード配列を表し、二重下線部は終止コドンを表す。また、いずれも、5’末端及び3’末端の両末端で連結された環状構造を形成する。なお、L126及びL126+stopは、それぞれC126及びC126+stopと同じ塩基配列を有しているが、環状構造を有しない直鎖状RNAである。
L126は、F35、F49、及びF42を、G1及びG2を鋳型としてリガーゼにより連結することによって合成した。リガーゼ反応は、5μMのF35、5μMのF49、15μMのF42、10μMのG1、20μMのG2、35units/μLのT4 DNAリガーゼ(タカラバイオ社製)、66mMのTris-HCl(pH7.6)、6.6mMのMgCl2、10mMのDTT、0.1mMのATP、10%(w/v)のPEG6000を含む反応液(反応液量:1.7mL)で行った。
具体的には、PEG6000及びT4 DNAリガーゼ以外を全て添加した反応液を90℃で3分間加熱した後、室温まで徐冷した。その後、当該反応液にPEG6000及びT4 DNAリガーゼを加え、37℃で約5時間インキュベートした。当該反応液に等量のクロロホルムを加えてPEG6000を抽出・除去した後、3Mの酢酸ナトリウム水溶液(pH5.2)及びイソプロピルアルコールを加えて冷却し、RNAを沈殿させて回収した。回収されたRNAの一部を変性PAGE分析(8% ポリアクリルアミド、7.5M 尿素、25% ホルムアミド、1×TBE)し、ゲルをSYBR Green II(タカラバイオ社製)により染色して可視化し、リガーゼ反応の進行を確認した後、同じく変性PAGEを用いて、残りのRNAから連結生成物(L126)を単離した。UV shadowing法により、目的物を含むバンドを可視化して切り出して細かく粉砕した後、溶出液[10mM EDTA(pH 8.0)]1mLで2回RNAを抽出した。得られた抽出液を遠心エバポレーターにより濃縮し、さらにマイクロコンYM-3(ミリポア社製)を用いて濃縮した。濃縮後の前記抽出液からRNAを、アルコール沈殿により脱塩・回収した。得られたRNA(L126) は超純水に溶解し、適宜希釈後UV吸収スペクトルを測定し、収量を算出した(収量:2.17nmol、収率:26%)。図2に、SYBR Green II(タカラバイオ社製)により変性PAGEゲル中の核酸を染色した結果に得られた染色像を示す。レーン1はssRNAマーカーを、レーン2は酵素反応前の反応液を、レーン3は酵素反応後の反応液を、それぞれアプライした。図2に示すように、酵素反応後には、F35、F49、及びF42からL126が合成された。
L126をリガーゼ反応により環状にすることによって、C126を合成した。リガーゼ反応は、1μMのL126、1μMのG3、17.5units/μLのT4 DNAリガーゼ(タカラバイオ社製)、6mMのTris-HCl(pH7.6)、6.6mMのMgCl2、10mMのDTT、0.1mMのATP、10%(w/v)のPEG6000を含む反応液(反応液量:2mL)で行った。
具体的には、PEG6000及びT4 DNAリガーゼ以外を全て添加した反応液を90℃で3分間加熱した後、室温まで徐冷した。その後、当該反応液にPEG6000及びT4 DNAリガーゼを加え、37℃で7時間インキュベートした。当該反応液に等量のクロロホルムを加えてPEG6000を抽出・除去した後、3Mの酢酸ナトリウム水溶液(pH5.2)及びイソプロピルアルコールを加えて冷却し、RNAを沈殿させて回収した。回収されたRNAの一部を変性PAGE分析(6% ポリアクリルアミド、7.5M 尿素、25% ホルムアミド、1×TBE)し、ゲルをSYBR Green II(タカラバイオ社製)により染色して可視化し、リガーゼ反応の進行を確認した後、同じく変性PAGEを用いて、残りのRNAから連結生成物(C126)を単離した。UV shadowing法により、目的物を含むバンドを可視化して切り出して細かく粉砕した後、溶出液[10mM EDTA(pH 8.0) ]0.5mLで2回RNAを抽出した。得られた抽出液を遠心エバポレーターにより濃縮し、さらにマイクロコンYM-3(ミリポア社製)を用いて濃縮した。濃縮後の前記抽出液からRNAを、アルコール沈殿により脱塩・回収した。得られたRNA(L126) は超純水に溶解し、適宜希釈後UV吸収スペクトルを測定し、収量を算出した(収量:0.40nmol、収率:20%)。図3に、SYBR Green II(タカラバイオ社製)により変性PAGEゲルを染色した結果に得られた染色像を示す。レーン1はssRNAマーカーを、レーン2は酵素反応前の反応液を、レーン3は酵素反応後の反応液を、それぞれアプライした。図3に示すように、酵素反応後には、L126からC126が合成された。
F42に代えてF42’を、G3に代えてG3’を、それぞれ用いた以外は、上記(2)及び(3)と同様にして、L126+stop及びC126+stopを合成した。
図1及び上記(2)で示すように、各フラグメントを適宜用いた以外は、上記(3)L126の合成及び(4)C126の合成と同様にして、C84、C168、C252を合成した。
図4に、L84(2分子のFLAGペプチドをコードする領域を有する84塩基の直鎖状RNA)を合成するためのリガーゼ反応の反応物を8%変性PAGE分析した結果に得られた染色像を示す。レーン1は酵素反応前の反応液を、レーン2は酵素反応後の反応液を、レーンMはssRNAマーカーを、それぞれアプライした。図4に示すように、酵素反応後には、F35及びF49からL84が合成された。
図5に、環状RNA合成反応の反応物を8%変性PAGE分析した結果に得られた染色像を示す。レーン1はL84を鋳型としたリガーゼ反応の反応前の反応液を、レーン2はL84を鋳型としたリガーゼ反応の反応後の反応液を、レーンMはssRNAマーカーを、レーン3はL126を鋳型としたリガーゼ反応の反応前の反応液を、レーン4はL126を鋳型としたリガーゼ反応の反応後の反応液を、それぞれ示す。図5に示すように、酵素反応後には、L84からC84及びC168が、L126からC126及びC252が、それぞれ合成された。
(7)L126、L126+stop、C126、C126+stopを鋳型とした無細胞翻訳反応
L126、L126+stop、C126、又はC126+stopを1μMとなるように無細胞翻訳液(PURExpress、New England Biolabs社製) に加え、37℃で3時間インキュベートした(反応液量:25μL)。対照として、RNA無添加の反応液も同様にインキュベートした。反応液から1μLサンプリングし、5μLの2×サンプル緩衝液[0.125M Tris-HCl(pH8.0)、2% SDS、30% グリセロール、0.02% ブロモフェノールブルー、5% 2-メルカプトエタノール]及び4μLの超純水と混合した。これを95℃で5分間加熱後、10-20% 勾配ポリアクリルアミドゲル(ATTO社製)を用いて電気泳動した(泳動用緩衝液: 25mM Tris-HCl、0.1% SDS、192mM グリシン)。ゲル中に展開されたタンパク質をPVDF膜(ミリポア社製)に転写後、マウス産生抗FLAG抗体、抗マウスIgG抗体ペルオキシダーゼ(HRP)複合体(いずれもSigma-Aldrich社製)と反応させ、HRP基質(SuperSignal West Femto Maximun Sensitivity Substrate、Thermo社製)を用いて、FLAG配列特異的にバンドを可視化(Light-Capture、ATTO社製)した。図6に、FLAGを含むタンパク質のバンドを可視化した結果を示す。レーン1はL126を添加した反応液、レーン2はL126+stopを添加した反応液、レーン3はC126+stopを添加した反応液、レーン4はC126を添加した反応液、レーン5はRNA無添加の反応液を、それぞれアプライした。図6に示すように、C126を添加した反応液では、C126+stopやL126を添加した反応液で合成された15~20kDaのタンパク質よりもはるかに長鎖のタンパク質が多く発現していた。特に、250kDa以上のタンパク質が発現しており、C126では、リボソームが10回以上回転して連続的に翻訳反応が進行し、タンパク質リピートが合成されていることが示唆された。
鋳型として、C84、C126、C168、又はC252を用いた以外は、上記(7)と同様にして、無細胞翻訳反応を行い、その後反応液を10-20% 勾配ポリアクリルアミドゲルを用いて電気泳動し、ゲル中に展開されたタンパク質をPVDF膜に転写後、FLAG配列特異的にバンドを可視化した。図7に、FLAGを含むタンパク質のバンドを可視化した結果を示す。レーン1及び3はRNA無添加の反応液、レーン2はC84を添加した反応液、レーン4はC126を添加した反応液、レーン5はC168を添加した反応液、レーン6はC252を添加した反応液を、それぞれアプライした。図7に示すように、C84を鋳型とした場合には、連続的翻訳反応の反応産物である長鎖ペプチドは生成しなかった。一方、C126、C168、及びC252を鋳型とした場合には、連続的翻訳反応の反応産物である長鎖ペプチド(タンパク質リピート)の生成が観察された。特に、C126及びC168を鋳型とした場合には、C252を鋳型とした場合よりも、翻訳効率が高く、より大量のタンパク質リピートが合成されていた。
複数のFLAGペプチドをコードする領域を有する真核細胞用環状RNAを合成し、これらを鋳型としてウサギ由来の無細胞系においてタンパク質を合成した。
<環状RNAの合成>
真核細胞用環状RNAは、ポリメラーゼによる転写反応を利用して合成した。まず、DNAオリゴヌクレオチドをDNA合成機で合成し(表3のFragment1~Fragment3;これらの配列を、配列番号15~17に示した)、T4 DNAリガーゼで連結させた後、アニーリング又はPCR法によって155、284、290、413塩基対の二本鎖DNAオリゴヌクレオチド(鋳型DNA)を合成した(表4及び5)。次いで、当該二本鎖DNAオリゴヌクレオチドを鋳型としてT7 RNAポリメラーゼによるin vitro転写を行い、129、258、264、387塩基の直鎖状の一本鎖RNAを合成し(表6及び7)、T4 RNAリガーゼを用いて5’末端と3’末端を連結して環状RNAを合成した。詳細を以下に示す。
ポリメラーゼ反応の鋳型とした各種オリゴヌクレオチドの配列を表3に示す。表3中、pは5’末端がリン酸化されていることを示す。
表3中、DNAオリゴヌクレオチドはβ-シアノエチルホスホロアミダイト試薬(Glen Research社製)を用い、H-8-SE DNA合成機(ジーンワールド社製)により合成した。Fragment1及びFragment2は、化学リン酸化試薬(Glen Research社製)を用いて5’末端をモノリン酸化した。各オリゴヌクレオチドは、定法に従い脱保護し、Micropure IIカートリッジ(Biosearch Technologies社製)により精製した。Fragment1、Fragment2、Fragment3、及びFragment1 DNA senseは、さらに変性PAGEにより精製した。
表3、及び配列表の配列番号18~35に記載の各種オリゴヌクレオチドを用いて、表4及び5に記載のin vitro転写反応の鋳型DNAを合成した。表4及び5中、下線部位はT7プロモーター配列を表す。
8×FLAG DNA(配列番号37)は、Adaptor1(配列番号18)を鋳型として、Fragment1(配列番号15)及びFragment2(配列番号16)をT4 DNAリガーゼを用いて連結させ、得られた連結物を変性PAGEにより精製することによってアンチセンス鎖を合成し、当該アンチセンス鎖とForward primer1(配列番号21)をPrimeSTAR(登録商標)HS DNA Polymerase(タカラバイオ社製)を用いてPCR法により二本鎖DNAを合成し、QIAquick PCR Purification Kit(QIAGEN社製)で精製することによって得た。
12×FLAG DNA(配列番号38)は、Adaptor2(配列番号19)及びAdaptor3(配列番号20)を鋳型として、Fragment1(配列番号15)、Fragment2(配列番号16)、及びFragment3(配列番号17)をT4 DNAリガーゼを用いて連結させ、得られた連結物を変性PAGEにより精製することによってアンチセンス鎖を合成し、当該アンチセンス鎖とForward primer1(配列番号21)をPrimeSTAR(登録商標)HS DNA Polymerase(タカラバイオ社製)を用いてPCR法により二本鎖DNAを合成し、QIAquick PCR Purification Kit(QIAGEN社製)で精製することによって得た。
8×FLAG(2) DNA(配列番号39)及び8×FLAG(stop) DNA(配列番号40)は、12×FLAG DNA(配列番号38)を鋳型として、それぞれForward primer1(配列番号21)及びReverse primer3(配列番号24)、又はForward primer1(配列番号21)及びReverse primer4(配列番号28)をプライマーとして、PrimeSTAR(登録商標)HS DNA Polymerase(タカラバイオ社製)を用いてPCR法により二本鎖DNAを合成し、QIAquick PCR Purification Kit(QIAGEN社製)で精製することによって得た。
8×FLAG(3) DNA(配列番号41)は、8×FLAG(2) DNA(配列番号39)を鋳型として、Forward primer2(配列番号35)及びReverse primer5(配列番号31)をプライマーとして、PrimeSTAR(登録商標)HS DNA Polymerase(タカラバイオ社製)を用いてPCR法により二本鎖DNAを合成し、QIAquick PCR Purification Kit(QIAGEN社製)で精製することによって得た。
8×FLAG(3 stop) DNA(配列番号42)は、8×FLAG(stop) DNA(配列番号40)を鋳型として、Forward primer2(配列番号35)及びReverse primer6(配列番号32)をプライマーとして、PrimeSTAR(登録商標)HS DNA Polymerase(タカラバイオ社製)を用いてPCR法により二本鎖DNAを合成し、QIAquick PCR Purification Kit(QIAGEN社製)で精製することによって得た。
表4に記載の鋳型DNAを用いて、表6及び7に記載の直鎖状の転写RNAを合成した。表6及び7中、囲み部分はKozak配列を表し、太字の塩基(AUG)は開始コドンを表し、下線部位はFLAGコード配列を表し、二重下線部は終止コドン(UGA、UAG、UAA)を表す。
Adaptor1(配列番号18)を用いて4×FLAG RNA(配列番号43)から4×FLAG RNA環化体(4×FLAG RNAの環状RNA)を、Adaptor2(配列番号19)を用いて8×FLAG RNA(配列番号44)から8×FLAG RNA環化体を、Adaptor3(配列番号20)を用いて12×FLAG RNA(配列番号45)から12×FLAG RNA環化体を、Adaptor4(配列番号29)を用いて8×FLAG(2) RNA(配列番号46)から8×FLAG(2) RNA環化体を、Adaptor5(配列番号30)を用いて8×FLAG(stop) RNA(配列番号47)から8×FLAG(stop) RNA環化体を、Adaptor6(配列番号33)を用いて8×FLAG(3) RNA(配列番号48)から8×FLAG(3) RNA環化体を、Adaptor7(配列番号34)を用いて8×FLAG(3 stop) RNA(配列番号49)から8×FLAG(3 stop) RNA環化体を、それぞれリガーゼ反応により合成した。リガーゼ反応は、1μMの転写RNA、5μMのDNAオリゴヌクレオチド(Adaptor1~7)、0.0125units/μLのT4 RNA リガーゼ2(ニュー・イングランド・バイオラボ社製)、50mM Tris-HCl(pH 7.5)、2mM MgCl2、1mM DTT、 0.4mM ATPを含む反応液(反応液量:800μL(但し、4×FLAG RNAの反応液は3000μL、8×FLAG RNA及び12×FLAG RNAの反応液は5000μL、8×FLAG(3) RNAの反応液は600μL、8×FLAG(3 stop) RNAの反応液は1000μLとした)で行った。
(5)ウサギ網状赤血球抽出液を用いた翻訳反応
1.843μMのRNA環化体又は1.843μMの環化前の直鎖状の転写RNAを65℃、3分間加熱後、氷水で急冷した後、ウサギ網状赤血球抽出液に添加し、翻訳反応を行った。具体的には、479.2nMの急冷後のRNA、70% Rabbit Reticulocyte Lysate(プロメガ社製)、10μM Amino Acid Mixture Minus Methionine、10μM Amino Acid Mixture Minus Leucine(いずれも、Rabbit Reticulocyte Lysate System(プロメガ社製)に付属)、0.8units/μL RNase Inhibitor(東洋紡社製)からなる反応液(反応液量:25μL)とし、各反応液を30℃で1.5~19時間インキュベートし、翻訳反応を行った。その後、各反応液から2.5μLをサンプリングし、2×SDSサンプル緩衝液[0.125M Tris-HCl(pH 8.0)、2% SDS、 30% グリセロール、0.02% ブロモフェノールブルー、5% 2-メルカプトエタノール]5μLと混合し、70℃で15分間加熱後、5%ポリアクリルアミドゲル又は10-20%勾配ポリアクリルアミドゲル(ATTO社製)を用いて電気泳動した(泳動用緩衝液: 25mM Tris-HCl、0.1% SDS、192mM グリシン)。ゲル中に展開されたタンパク質をPVDF膜(ミリポア社製)に転写後、マウス産生抗FLAG抗体、抗マウスIgG抗体ペルオキシダーゼ(HRP)複合体(いずれもSigma-Aldrich社製)と反応させ、HRP基質(SuperSignal West Femto Maximun Sensitivity Substrate、Thermo社製)を用いて、FLAG配列特異的にバンドを可視化(Light-Capture、ATTO社製)した。図11~14に、FLAGを含むタンパク質のバンドを可視化した結果を示す。図11~14の各レーンには、それぞれ、表8~11に記載の反応液をアプライした。
実施例2で合成されたRNA環化体及び環化前の直鎖状の転写RNAを鋳型として、ヒト由来の無細胞系においてタンパク質を合成した。
鋳型RNAを終濃度1.2μMとなるように、AvidExpress(登録商標)Cell-Free Translation System(ヒトHeLaS3細胞由来、Avidity社製)を用いて製品マニュアルどおりに翻訳反応を行った。反応終了後、各反応液から2.5μLをサンプリングし、実施例2と同様にして10-20%勾配ポリアクリルアミドゲルを用いて電気泳動し、ゲル中に展開されたタンパク質をPVDF膜に転写後、抗FLAG抗体、抗マウスIgG抗体HRP複合体を反応させ、HRP基質と反応させることでFLAG配列特異的なタンパク質のバンドを可視化した。
実施例2で合成されたRNA環化体及び環化前の直鎖状の転写RNAを鋳型として、ヒト細胞内の翻訳系を用いてタンパク質を合成した。
まず、細胞培養用12ウェルプレート(日本ベクトン・ディッキンソン社製)に、1ウェルあたりOpti-MEM I Reduced-Serum Medium(インビトロジェン社製)145μL及び2.4μMの鋳型RNA溶液5μLを混合し、Lipofectamine RNAiMAX(インビトロジェン社製)2μLを添加して混合し、15分間静置した。その後、10%ウシ胎児血清(インビトロジェン社製)を含有させたDulbecco’s Modified Eagle Medium(和光純薬工業社製)を用いて1mLあたり100,000個に希釈したHeLa細胞(ヒト子宮頸部癌由来の培養細胞株、理化学研究所バイオリソースセンターより提供)を850μL添加して37℃、5% CO2環境下で24時間培養した(RNA終濃度:12nM)。1ウェルあたり細胞溶解バッファー(CSTジャパン社製)200μLを添加して細胞を溶解させた後、遠心分離処理を行った。得られた上清7.5μLをサンプリングし、実施例2と同様にして10-20%勾配ポリアクリルアミドゲルを用いて電気泳動し、ゲル中に展開されたタンパク質をPVDF膜に転写した。その後、抗FLAG抗体又は抗アクチン抗体(Santa Cruz Biotechnology社製)、抗マウスIgG抗体HRP複合体を反応させ、HRP基質と反応させることによって、FLAG配列特異的なタンパク質のバンド又はアクチンタンパク質のバンドを可視化した。
本実施例により、本発明の真核細胞用環状RNAを哺乳細胞内へ導入することにより、回転式タンパク質翻訳を行うことが可能であることが示された。
実施例2で合成されたRNA環化体及び環化前の直鎖状の転写RNAを鋳型として、ヒト細胞内の翻訳系を用いてタンパク質を合成した。
まず、細胞培養用24ウェルプレート(日本ベクトン・ディッキンソン社製)に、1ウェルあたりOpti-MEM I Reduced-Serum Medium(インビトロジェン社製)45μL及び2μMの鋳型RNA溶液4μLを混合し、Lipofectamine RNAiMAX(インビトロジェン社製)1μLを添加して混合し、15分間静置した。その後、10%ウシ胎児血清を含有したDulbecco’s Modified Eagle Medium(和光純薬工業社製)を用いて1mLあたり143,000個に希釈したHeLa細胞を350μL添加して37℃、5% CO2環境下で24時間培養した(RNA終濃度:20nM)。1ウェルあたり細胞溶解バッファー(CSTジャパン社製)30μLを添加して細胞を溶解させた後、遠心分離処理を行った。得られた上清のタンパク量をCoomassie Plus(サーモフィッシャーサイエンティフィック社製)を用いて測定し、細胞溶解バッファーを用いてタンパク濃度を1.5 mg/mLに調製した。タンパク質濃度調整後に、7.5μLをサンプリングし、実施例2と同様にして10-20%勾配ポリアクリルアミドゲルを用いて電気泳動し、ゲル中に展開されたタンパク質をPVDF膜に転写した。その後、抗FLAG抗体又は抗アクチン抗体(Santa Cruz Biotechnology社製)、抗マウスIgG抗体HRP複合体を反応させ、HRP基質と反応させることによって、FLAG配列特異的なタンパク質のバンド又はアクチンタンパク質のバンドを可視化(ChemiDoc XRS Plus、バイオ・ラッド ラボラトリーズ社製)した。
実施例2の(4)で合成された8×FLAG RNAの環状RNAをHeLa細胞にトランスフェクションし、蛍光標識した抗-FALG抗体を用いた細胞染色により、細胞内に導入したRNAの翻訳産物の検出を行った。
まず、カバーガラスを各ウェルに入れた細胞培養用24ウェルプレート(日本ベクトン・ディッキンソン社製)に、10%ウシ胎児血清を含有したDulbecco’s Modified Eagle Medium(和光純薬工業社製)を用いて、1mLあたり100,000個に希釈したHeLa細胞を1ウェル当たり500μl添加して、37℃、5% CO2環境下で一晩培養した。その後、各ウェルから培地を除き、Opti-MEM I Reduced-Serum Medium(インビトロジェン社製)を200μL添加した。Opti-MEM I Reduced-Serum Medium(インビトロジェン社製)32.5μL及び2μg/mLの鋳型RNA溶液2.5μLを混合し、この溶液にOpti-MEM I Reduced-Serum Medium(インビトロジェン社製)12μL及びOligofectamine(インビトロジェン社製)3μLを混合した溶液を添加し、15分間静置した後、各ウェルに加え、37℃、5% CO2環境下で6時間培養した。
トランスフェクション6時間後、培地を取り除き、10%ウシ胎児血清を含有したDulbecco’s Modified Eagle Medium(和光純薬工業社製)を1ウェル当たり500μL加え、更に37℃、5%CO2環境下で24時間培養した。その後、培地を取り除き、洗浄後、4%PFA/PBSで細胞を固定化した。0.3%Triton X-100/PBSで細胞を処理し、次いで1%BSA/PBSでブロッキングを行った後、1%BSA/PBSで調製したマウス抗-FLAG抗体(シグマアルドリッチジャパン合同会社製)を添加して、1時間インキュベートした。洗浄後、1%BSA/PBSで調製したAlexa Flour 488標識抗-マウスIgG抗体(ライフテクノロジーズ・ジャパン株式会社製)を添加して、1時間インキュベートした。洗浄後、顕微鏡観察を行った。結果を図18、19に示す。
Claims (8)
- タンパク質をコードし、全長の塩基数が102以上の3の倍数であり、少なくとも1の開始コドンを有し、前記開始コドンと同じ読み枠の終止コドンを有しておらず、さらにIRES(Internal ribosome entry site)を含んでいない、環状RNA。
- 全長の塩基数が561以下である、請求項1に記載の環状RNA。
- 前記開始コドンの上流にKozak配列を有する請求項1又は2に記載の環状RNA。
- 真核細胞の発現系において、請求項1~3のいずれか一項に記載の環状RNAを鋳型として、当該環状RNAがコードしているタンパク質を発現させる、タンパク質の製造方法。
- 請求項1~3のいずれか一項に記載の環状RNAを真核細胞に導入する、又は請求項1~3のいずれか一項に記載の環状RNAを真核細胞由来の無細胞発現系に添加することにより、当該環状RNAがコードしているタンパク質を発現させる請求項4に記載のタンパク質の製造方法。
- 前記真核細胞が哺乳細胞である、請求項4又は5に記載のタンパク質の製造方法。
- タンパク質をコードし、全長の塩基数が102以上360以下の3の倍数であり、少なくとも一つの原核細胞由来のリボソームが認識するリボソーム結合部位と、前記リボソーム結合部位の下流1~20塩基以内に一つの開始コドンを有し、前記開始コドンと同じ読み枠の終止コドンを有していない、環状RNA。
- 原核細胞の発現系において、請求項7に記載の環状RNAを鋳型として、当該環状RNAがコードしているタンパク質を発現させる、タンパク質の製造方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/376,665 US9353153B2 (en) | 2012-02-09 | 2013-02-08 | Cyclic RNA and protein production method |
JP2013557601A JP6284181B2 (ja) | 2012-02-09 | 2013-02-08 | 環状rna及びタンパク質の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012026506 | 2012-02-09 | ||
JP2012-026506 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013118878A1 true WO2013118878A1 (ja) | 2013-08-15 |
Family
ID=48947633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/053095 WO2013118878A1 (ja) | 2012-02-09 | 2013-02-08 | 環状rna及びタンパク質の製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9353153B2 (ja) |
JP (1) | JP6284181B2 (ja) |
WO (1) | WO2013118878A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109971775A (zh) * | 2017-12-27 | 2019-07-05 | 康码(上海)生物科技有限公司 | 一种核酸构建物及其调控蛋白合成的方法 |
US11203767B2 (en) | 2018-06-06 | 2021-12-21 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
WO2022219915A1 (ja) * | 2021-04-12 | 2022-10-20 | NUProtein株式会社 | 塩基配列変換装置、塩基配列変換方法、ポリヌクレオチド、ポリヌクレオチドを作製する方法、およびプログラム |
US11603396B2 (en) | 2019-05-22 | 2023-03-14 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11679120B2 (en) | 2019-12-04 | 2023-06-20 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
WO2023167276A1 (ja) * | 2022-03-04 | 2023-09-07 | 国立研究開発法人科学技術振興機構 | キャップ化rna及びその製造方法並びにタンパク質の製造装置及びタンパク質の製造方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200306286A1 (en) | 2017-12-15 | 2020-10-01 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
US20230181620A1 (en) | 2020-01-29 | 2023-06-15 | Flagship Pioneering Innovations Vi, Llc | Compositions for translation and methods of use thereof |
WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007825A1 (en) * | 1995-08-23 | 1997-03-06 | The Regents Of The University Of Colorado | Circular rna and uses thereof |
WO2003002713A2 (en) * | 2001-06-26 | 2003-01-09 | Abgenix, Inc. | Antibodies to opgl |
WO2010038155A2 (en) * | 2008-09-30 | 2010-04-08 | Medical Research Council | Antibodies against il-25 |
WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
-
2013
- 2013-02-08 WO PCT/JP2013/053095 patent/WO2013118878A1/ja active Application Filing
- 2013-02-08 JP JP2013557601A patent/JP6284181B2/ja active Active
- 2013-02-08 US US14/376,665 patent/US9353153B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007825A1 (en) * | 1995-08-23 | 1997-03-06 | The Regents Of The University Of Colorado | Circular rna and uses thereof |
WO2003002713A2 (en) * | 2001-06-26 | 2003-01-09 | Abgenix, Inc. | Antibodies to opgl |
WO2010038155A2 (en) * | 2008-09-30 | 2010-04-08 | Medical Research Council | Antibodies against il-25 |
WO2010037835A2 (en) * | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
Non-Patent Citations (2)
Title |
---|
CHEN CHANG-YOU ET AL.: "Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs", SCIENCE, vol. 268, 1995, pages 415 - 417 * |
PERRIMAN RHONDA ET AL.: "Circular mRNA can direct translation of extremely long repeating- sequence proteins in vivo", RNA, vol. 4, 1998, pages 1047 - 1054 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109971775B (zh) * | 2017-12-27 | 2021-12-28 | 康码(上海)生物科技有限公司 | 一种核酸构建物及其调控蛋白合成的方法 |
CN109971775A (zh) * | 2017-12-27 | 2019-07-05 | 康码(上海)生物科技有限公司 | 一种核酸构建物及其调控蛋白合成的方法 |
US11352641B2 (en) | 2018-06-06 | 2022-06-07 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11845950B2 (en) | 2018-06-06 | 2023-12-19 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11352640B2 (en) | 2018-06-06 | 2022-06-07 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11447796B2 (en) | 2018-06-06 | 2022-09-20 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11203767B2 (en) | 2018-06-06 | 2021-12-21 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11981909B2 (en) | 2018-06-06 | 2024-05-14 | Massachusetts Institute Of Technology | Circular RNA for translation in eukaryotic cells |
US11603396B2 (en) | 2019-05-22 | 2023-03-14 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11802144B2 (en) | 2019-05-22 | 2023-10-31 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11679120B2 (en) | 2019-12-04 | 2023-06-20 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11766449B2 (en) | 2019-12-04 | 2023-09-26 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
US11771715B2 (en) | 2019-12-04 | 2023-10-03 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
WO2022219915A1 (ja) * | 2021-04-12 | 2022-10-20 | NUProtein株式会社 | 塩基配列変換装置、塩基配列変換方法、ポリヌクレオチド、ポリヌクレオチドを作製する方法、およびプログラム |
WO2023167276A1 (ja) * | 2022-03-04 | 2023-09-07 | 国立研究開発法人科学技術振興機構 | キャップ化rna及びその製造方法並びにタンパク質の製造装置及びタンパク質の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US9353153B2 (en) | 2016-05-31 |
JPWO2013118878A1 (ja) | 2015-05-11 |
US20150079630A1 (en) | 2015-03-19 |
JP6284181B2 (ja) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6284181B2 (ja) | 環状rna及びタンパク質の製造方法 | |
CN107208096A (zh) | 基于crispr的组合物和使用方法 | |
CN110462034A (zh) | 化脓链球菌cas9突变基因和由其编码的多肽 | |
US10590456B2 (en) | Ribosomes with tethered subunits | |
US9255274B2 (en) | Protein-responsive translational regulatory system using RNA-protein interacting motif | |
CN113166737A (zh) | 提高转录的rna的加帽效率的方法和组合物 | |
Rieder et al. | Experimental tools to identify RNA-protein interactions in Helicobacter pylori | |
CN110408636B (zh) | 多重标签串联的dna序列及其在蛋白质表达纯化***的应用 | |
JP4936290B2 (ja) | 非天然型アミノ酸を組み込んだタンパク質の製造方法 | |
EP4041249A1 (en) | Compositions and methods for in vivo synthesis of unnatural polypeptides | |
WO2015184283A1 (en) | Tethered ribosomes and methods of making and using thereof | |
Stewart et al. | Modular RNA motifs for orthogonal phase separated compartments | |
JP4804525B2 (ja) | 翻訳同伴システムを利用した抗菌ペプチドの大量発現方法 | |
CN102703400A (zh) | 热启动dna聚合酶及其应用 | |
US20210187102A1 (en) | Method of obtaining a polyepitopic protein and polyepitopic dna vector | |
US11629366B2 (en) | Method for selective translation of desired proteins in the presence of a specified nucleic acid ligand | |
Liu | Structure of mammalian RNA polymerase II elongation complex bound by α-amanitin and study of mammalian transcription termination and 3’end processing | |
JP6626909B2 (ja) | 標的タンパク質の可溶化用組成物及びその用途 | |
JP4198387B2 (ja) | 無細胞タンパク質合成系におけるタンパク質またはペプチドの製造方法、およびこれを用いて製造したタンパク質またはペプチド | |
WO2022271965A3 (en) | Compositions and methods for improved protein translation from recombinant circular rnas | |
WO2023023487A1 (en) | Screening codon-optimized nucleotide sequences | |
WO2021231503A2 (en) | Systems and methods for enhancing gene expression | |
CN117070514A (zh) | 非天然rna的制备方法及产品 | |
CN116987682A (zh) | 一种催化花椒毒酚生成花椒毒素的o-甲基转移酶及其编码基因与应用 | |
Jo et al. | A simple method for constructing a tagged protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13747232 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013557601 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14376665 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13747232 Country of ref document: EP Kind code of ref document: A1 |